This new regulatory milestone opens up growth opportunities in heart health for food and beverage manufacturers
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and life sciences, today announced that a new heart health claim for isolated soy protein has been accepted by the Food Standards Australia New Zealand (FSANZ). The approval allows food and beverage manufacturers in Australia and New Zealand to link the consumption of soy proteins to healthy blood cholesterol levels.
Ce communiqué de presse contient des éléments multimédias. Voir le communiqué complet ici : businesswire.com
“For decades, IFF has invested in the science behind soy proteins and its role in supporting cardiovascular health,” said Tony Andrew, Vice President of Protein Solutions for IFF Food Ingredients. “This approved claim validates years of rigorous research and collaboration. With our deep expertise in ingredient science, application, and scale, we are well-positioned to help our clients translate this new milestone into products that deliver on health, taste, and sustainability.”
The claim is supported by a multi-year intercontinental research collaboration supported by IFF, the Soy Nutrition Institute Global, and the Soybean Export Council of the United States, with researchers from Australia and the University of Toronto. Under the new authorization, foods formulated to help consumers achieve a daily intake of 20 to 25 grams of isolated soy proteins, consumed as part of a healthy and balanced diet, can carry the heart health claim.
Isolated soy protein is a high-quality plant-based protein with 90% completeness, containing the nine essential amino acids. Its functional versatility makes it widely used in beverages, dairy alternatives, nutrition bars, snacks, and plant-based foods, categories where consumers are increasingly seeking products that combine taste with clinically supported benefits. This approval marks a significant milestone for plant-based nutrition, offering brands new opportunities to develop products positioned to support heart health.
“Clinical evidence supports a causal relationship between isolated soy protein consumption and improvement in blood lipids,” said Dr. Alan Barclay, Ph.D., lead author of the submission to FSANZ. “With dyslipidemia affecting around 60% of Australian adults and many New Zealanders, the daily consumption of soy proteins offers a practical food-based nutritional strategy to help manage cholesterol and reduce cardiovascular risk.”
Australia and New Zealand join 11 other countries, including the United States, Canada, and Japan, in recognizing the link between soy protein consumption and heart health. Supported by decades of research and innovation in the SOLAE SUPRO soy protein portfolio, IFF is working with food and beverage manufacturers in the region to develop next-generation products that combine nutrition science, functionality, and consumer appeal.
For more information, please visit iff.com.
Welcome to IFF
At IFF (NYSE: IFF), we create joy through science, creativity, and passion. As a global leader in taste, fragrances, food ingredients, health, and biosciences, we innovate for the future. Every day, we deliver revolutionary and sustainable solutions that enhance the products people love, promote well-being, delight the senses, and enrich the human experience. To learn more, visit iff.com, LinkedIn, Instagram, and Facebook.
© 2026 by International Flavors & Fragrances Inc. IFF is a registered trademark. All rights reserved.
The text of the press release from a translation should not in any way be considered official. The only version of the statement that is binding is that of the original language. The translation should always be compared to the source text, which will prevail.
Consult the original version on businesswire.com: businesswire.com
